Nykode Therapeutics is a leading clinical-stage biopharmaceutical company that is breaking boundaries to revolutionize drug design and shape the future of medicine. With their intelligent modular platform and tailored hyper-targeting, Nykode is unlocking unlimited possibilities in the field of medicine. The company's core values form a strong foundation for their positions, principles, and policies, guiding everything they do.

They are driven by a robust strategy to accelerate their existing assets through the clinical stage, explore the potential of their platform to expand their pipeline, and establish strategic partnerships to enhance their capabilities. Nykode's board of directors provides unrivaled collective experience, steering and supporting the fast-moving company. Their management team possesses the combined skills and expertise necessary to maximize the value of their platform and deliver their vision.

Founded in 2006, Nykode Therapeutics is inspired by the technology developed at the University of Oslo and Oslo University Hospital. They have a rich history rooted in the pioneering work of Professor Bjarne Bogen and Professor Inger Sandlie. Headquartered in Oslo, Norway, Nykode Therapeutics is at the forefront of innovative biopharmaceutical research and development